-

Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February 24, 2026. The company will hold the earnings conference call at 4:30 pm ET.

The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus’ Investor Relations website. Alternatively, the call can be accessed via the following:

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus Communications
Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Tempus Communications
Hanah Heintzelman
hanah.heintzelman@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

More News From Tempus AI, Inc.

Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Merck, known as MSD outside of the United States and Canada, today announced an expanded, multi-year collaboration aimed at accelerating the discovery and development of precision medicine biomarkers and supporting Merck’s oncology and potentially broader therapeutic portfolios. “This collaboration builds on our existing relationship and reflects our shared...

Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Morgan Stanley Technology, Media, and Telecom Conference on Tuesday, March 3 in San Francisco. Eric Lefkofsky, Tempus Founder and CEO, will participate in a fireside chat at 9:15 AM PST. The live webcast may be accessed directly using the following link: https://event.webcasts.com/starthere.jsp?ei=1753938&tp_k...

Tempus Reports Fourth Quarter and Full Year 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2025. Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry) Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hered...
Back to Newsroom